Agoraphobia
Conditions
Keywords
Hypnosis, Wait-list
Brief summary
The purpose of the study is to compare the efficacy of Hypnotherapy for the treatment of Agoraphobia compared to a wait-list control group.
Detailed description
With the present study, the efficacy of 8-12 sessions of individual Hypnotherapy will be compared to a wait-list control groups. At study entry and at the end of treatment with Hypnotherapy, the Agoraphobia symptoms will be assessed via clinician-rating and self-report. It is expected that Hypnotherapy will be superior to a wait-list control regarding the percentage reduction of the anxiety symptoms after three months of treatment.
Interventions
BEHAVIORALHypnotherapy for Agoraphobia
see description of the experimental arm
Sponsors
University Hospital Tuebingen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent * Patient fulfills DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) criteria for agoraphobia * 18 - 65 years of age * Sufficient knowledge of the German language in order to participate in the study * Sufficient availability to participate in weekly therapy sessions
Exclusion criteria
* Acute suicidality (intended action, concrete plans or intermittent pronounced suicidal ideation) * Lifetime diagnosis of a bipolar disorder or psychotic disorder * Alcohol or substance use disorder without abstinence in the last 12 months * Severe cognitive impairments (in cases of suspicion evaluation via Mini Mental State Test (MMST) \< 26, will be conducted) * Other severe primary mental disorders to be treated: severe Major Depressive Disorder, severe personality disorder of borderline type with self-injury, severe combined personality disorder, actual posttraumatic stress disorder, anorexia nervosa, obsessive compulsive disorder * Somatic disorder impeding participation in regular psychotherapy sessions * Outpatient psychotherapy during the last twelve months. * Medication with anxiolytics or anti-psychotics (antidepressant medication is permitted if stable since more than eight weeks and no planned changes during the duration of therapy)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Panic and Agoraphobia Scale (PAS) | Between baseline (t1) and after 12 weeks (t2) | The clinician-rating PAS will be used to measure the symptom severity (range 0-56 with higher values indicating more symptoms) for the primary outcome that is defined as the (mean) percentage change of the total symptom score between baseline (t1) and after 12 weeks (t2). |
Countries
Germany
Outcome results
None listed